首页> 中文期刊> 《实用医学杂志》 >基于转录组测序的候选膀胱尿路上皮癌分子标记的识别

基于转录组测序的候选膀胱尿路上皮癌分子标记的识别

         

摘要

目的:探讨基于Illumina平台的转录测序筛选出的膀胱癌的候选分子标记物在临床诊断中的可能应用价值。方法:对中南大学湘雅医学院附属海口医院2011-2013年31例膀胱尿路上皮癌和对应的正常组织,采用实时荧光定量PCR对转录组测序筛选出的候选基因进行验证。结果:筛选出的4个候选基因, CDH1、CLDN7、VEGFA和PTPRF在转录组测序患者肿瘤组织相对于正常组织表达上调;实时荧光定量PCR对更多的患者验证发现,CDH1、VEGFA、PTPRF和CLDN7中,VEGFA相对表达水平上调,差异有统计意义(P<0.05),VEGFA和PTPRF表达相对上调,但差异无统计学意义(P>0.05);PTPRF和肿瘤的初发和复发关系比较密切(P=0.002),其预测敏感度和特异度分别为90.0%和83.3%。结论:VEGFA在膀胱尿路上皮癌的发生发展中起重要作用,有望成为膀胱尿路上皮癌的分子标志物,PTPRF有望作为预测膀胱肿瘤复发的分子参考指标。%Objective To explore the dignostic value of the candidate molecular markers in Urothelium carcinoma based on Illumina Transcriptome Sequencing. Methods Candidate genes which were screened with transcriptome sequencing were validated by using real-time fluorescent quantitative PCR in 31 pairs of tumor and normal tissues of Urothelium carcinoma patients from Affliated Hai kou Hospital Xiangya School of Medicine Central South University. Results The four candidate genes (CDH1,VEGFA,PTPRF and CLDN7) in tumor tissues were up-regulated compared with normal groups in samples of sequencing. The relative expression of VEGFA mRNA were higher than that in normal tissues. There were significant difference in two groups (P<0.05). PTPRF and CLDN7 were also up-regulated, but no significant difference was found (P > 0.05). PTPRF was closely related with the recurrence of tumor (P=0.002), and the predict sensitivity and speciality rate were 90.0%and 83.3%respectively. Conclusions CDH1 and VEGFA play important roles in the occurrence and development of bladder urothelial carcinoma, and they may be the possible biomarkers. PTPRF is expected to be a molecular reference recurrent predictor of bladder tumor.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号